Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and ...

Cipla’s abbreviated new drug application for a generic version of Bristol Myers Squibb’s cancer drug Abraxane has received final approval from the U.S. Food and Drug Administration. The final ...

Cipla's protein-bound paclitaxel is a generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane for injectable suspension 100 mg/vial.